Stock Worth Mentioning Today: Could Juno Therapeutics Inc See a Reversal After Breaking Its 1 Year Low?

Stock Worth Mentioning Today: Could Juno Therapeutics Inc See a Reversal After Breaking Its 1 Year Low?

The stock of Juno Therapeutics Inc (NASDAQ:JUNO) hit a new 52-week low and has $19.60 target or 4.00% below today’s $20.42 share price. The 7 months bearish chart indicates high risk for the $2.05 billion company. The 1-year low was reported on Nov, 23 by Barchart.com. If the $19.60 price target is reached, the company will be worth $82.00M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 4.53M shares traded hands or 212.41% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 32.60% since April 21, 2016 and is downtrending. It has underperformed by 37.93% the S&P500.

Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.

Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage

Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $73 is the highest target while $39 is the lowest. The $51.80 average target is 153.67% above today’s ($20.42) stock price. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, July 6 by Barclays Capital. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Neutral” rating by Goldman Sachs on Wednesday, November 18. Maxim Group maintained Juno Therapeutics Inc (NASDAQ:JUNO) rating on Friday, August 5. Maxim Group has “Buy” rating and $50 price target. The company was downgraded on Thursday, October 29 by Standpoint Research. As per Thursday, February 25, the company rating was initiated by Citigroup. The stock has “Neutral” rating given by JP Morgan on Friday, July 8. The company was initiated on Tuesday, August 18 by FBR Capital. FBR Capital maintained the stock with “Outperform” rating in Friday, July 8 report. The firm earned “Buy” rating on Monday, August 24 by Standpoint Research. Standpoint Research upgraded Juno Therapeutics Inc (NASDAQ:JUNO) on Tuesday, December 15 to “Buy” rating.

According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Global X Management Lc last reported 230 shares in the company. Raymond James Associates last reported 5,839 shares in the company. Thompson Davis And Incorporated accumulated 0.11% or 1,750 shares. Profund Advsr Ltd Com holds 0.07% or 39,877 shares in its portfolio. 1832 Asset Mngmt Ltd Partnership last reported 95,200 shares in the company. Omers Administration Corporation accumulated 48,500 shares or 0.04% of the stock. Benjamin F Edwards Co has invested 0.02% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). The New York-based Amalgamated Bank has invested 0.02% in Juno Therapeutics Inc (NASDAQ:JUNO). Moreover, Citadel Ltd Liability has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 41,119 shares. Dekabank Deutsche Girozentrale reported 60,000 shares or 0.03% of all its holdings. Bamco Ny owns 100,525 shares or 0.02% of their US portfolio. Panagora Asset Management Inc holds 2,710 shares or 0% of its portfolio. Rhumbline Advisers last reported 55,351 shares in the company. Bb Biotech Ag accumulated 1.31 million shares or 1.98% of the stock. Tower Research Capital Limited Liability Co (Trc) last reported 70 shares in the company.

More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Businesswire.com which released: “Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold” on November 23, 2016, also Fool.com published article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics”, Schaeffersresearch.com published: “Buzz Stocks: Juno Therapeutics Inc, Eli Lilly and Co, and Biogen Inc” on November 23, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Fool.com and their article: “Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals” with publication date: October 28, 2016.

JUNO Company Profile

Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment